Sign up
Pharma Capital

Genetic Technologies’ shares surge on launching promotional campaign

The company’s lead product is a risk assessment test for non-hereditary breast cancer.
a woman getting a breast examination
Genetic Technologies markets BREVAGenplus through its U.S. subsidiary

Genetic Technologies (ASX:GTG) has launched a three-month promotional campaign in conjunction with Breast Cancer Awareness Month which takes place throughout October 2017.

The company’s shares were last trading 33% higher intra-day, at US$0.008.

Genetic Technologies’ lead product, BREVAGenplus, is a clinically validated risk assessment test for non-hereditary breast cancer.

The test assesses both clinical risk factors and genetic markers known to be associated with non-hereditary breast cancer to determine a woman's five-year risk of developing the disease.

As part of the promotion, the BREVAGenplus test will be offered at a special reduced price of US$199.00 compared to its standard list price of US$349.00.

In April 2017, BREVAGenplus was repositioned from a traditional reimbursement system, through insurance providers, to a direct patient self-pay program.

The initiative was implemented to better serve healthcare providers and patients by providing a streamlined, easy to use billing and payment system.

Genetic Technologies markets BREVAGenplus, through its U.S. subsidiary Phenogen Sciences Inc., to healthcare professionals in comprehensive breast health care and imaging centres.

The company also markets to obstetricians/gynaecologists and breast cancer risk assessment specialists.

Register here to be notified of future GTG Company articles
View full GTG profile View Profile
View All

Related Articles

If UniBio’s plans come to fruition it won’t be too long before the company orchestrates a major adjustment to the food-chain.

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.